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Introduction
The major discoveries that led to the modern era of work
on systemic lupus erythematosus (SLE) were those of
Hargraves et al. in 1947 of the lupus erythematosus (or
‘LE’) cell phenomenon [1], followed by the discovery of
autoreactivity to nuclei [2,3] and to nucleoprotein [4].
Contemporaneous with these findings came the discovery
that complement levels were abnormal in patients with
SLE [5,6] and the discovery a few years later that comple-
ment was deposited in inflammatory lesions in tissues [7].
These findings led to a model for the pathogenesis of SLE
in which autoantibodies formed immune complexes with
their autoantigens, the resulting immune complexes acti-
vated complement, and the products of complement acti-
vation caused tissue injury and disease.
Subsequent findings have shown that the associations of
complement with SLE are much more complex and it is
now clear that complement may be friend as well as foe.
The first finding was of a rare subgroup of patients with
SLE with inherited homozygous deficiencies of certain
complement proteins, particularly proteins of the early part
of the classical pathway of complement activation. Subse-
quently it was discovered that up to a third of patients with
SLE had high levels of autoantibodies to some comple-
ment proteins, especially to C1q, the very first protein in
the classical pathway of complement.
These data allowed three deductions to be made about
the association of complement with SLE. The first is that
SLE is associated with complement activation, which may
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cause tissue injury. The second is that hereditary comple-
ment deficiency may cause SLE. The third is that the
disease processes in SLE cause the development of
autoantibodies to certain complement proteins. At first
sight these statements appear to be mutually contradic-
tory and difficult to reconcile one with the other.
In this chapter I will illustrate the evidence in support of
these three deductions and develop some hypotheses
that may explain these complex abnormalities of the com-
plement system found in association with SLE.
The first section of this review will first describe the clinical
associations of complement abnormalities with SLE, fol-
lowed by the mechanisms of these associations. Finally a
hypothesis will be proposed to explain the associations
and consider the therapeutic implications.
Complement and SLE: the clinical
observations
Complement is activated in SLE
Complement activation is easy to demonstrate in the
plasma and tissues of patients with SLE. Indeed measures
of complement activation are part of the standard reper-
toire of laboratory tests to which most patients with SLE
are subjected on a regular basis. In this section I will
describe the evidence for complement activation in
plasma, on cells and in tissues. I will also discuss abnor-
malities that have been discovered in an important com-
plement receptor, complement receptor type 1 (CR1),
expressed on erythrocytes and cells of the immune
system. I will review the evidence that measurements of
complement activation correlate with disease activity, and
the value of such measurements in the assessment and
management of patients with SLE.
Complement activation in plasma
Assays of complement levels in serum are one of the stan-
dard assays used to assist the clinical management of
patients with SLE [8]. The majority of laboratories measure
antigenic concentrations of C3 and C4. A smaller number
of laboratories also routinely provide a functional measure-
ment of the activity of the whole complement pathway
from classical pathway activation through to formation of
the membrane attack complex, such as the CH50 (com-
plement haemolysis 50%) test.
The dominant pathway for complement activation in SLE is
the classical pathway, triggered by the interaction of C1q
with immune complexes. Classical pathway complement
protein levels are reduced in association with active
disease, especially C1, C4 and C2 levels. Levels of C3
are typically at the lower end of the normal range and only
occasionally severely depressed. Levels of C3 are main-
tained because of the regulatory mechanisms that control
classical pathway complement activation in vivo, espe-
cially the activity of C4 binding protein that inhibits classi-
cal pathway activation [9]. When C3 levels are reduced,
this is usually associated with reduced levels of factor B,
indicating amplification of C3 turnover in vivo by the ampli-
fication loop of the alternative pathway [10,11].
Complement levels, however, provide a rather poor surro-
gate of clinical disease activity [12–14] for four reasons.
Firstly, there is wide variation in normal complement
protein levels between different individuals, partly due to
genetic polymorphisms and partly for unknown reasons.
The second reason is that protein levels are controlled by
the balance of protein synthesis and catabolism, and the
increase in catabolism of complement proteins caused by
immune complexes in SLE is balanced by a variable
response in complement protein synthetic rates between
individuals [15–17]. As an additional factor that affects
protein synthetic rates, many complement proteins are
acute phase reactants, including C3 and C4. Such pro-
teins display an increase in synthetic rate in response to
inflammatory stimuli, which may compensate for the hyper-
catabolism of complement secondary to complement acti-
vation [18]. Thirdly, measurement of complement levels in
serum may not reflect accurately what is occurring in
tissues. This can be illustrated by diseases such as myas-
thenia gravis in which complement activation occurs at the
motor neurone end plate [19,20], or membranous nephri-
tis in which complement activation occurs at the suben-
dothelial surface of the glomerular basement membrane
[21,22]. Experimental models show that, in these dis-
eases, complement activation is a key part of the inflam-
matory injury, but complement activation is virtually
undetectable in peripheral blood. By contrast, when com-
plement activation occurs in peripheral blood, for example
in autoimmune haemolytic anaemia, then serum levels of
C4 and C3 may be severely reduced. The fourth reason
why complement levels are a poor surrogate of disease
activity is that autoantibodies to complement proteins,
especially to C1q, may be associated with profound acti-
vation of the complement pathway in vivo, and the level of
complement activation may be associated with the levels
of these autoantibodies rather than by disease per se.
Autoantibodies to C1q are reviewed later in this chapter.
In patients with established disease, regular measurement
of complement activity is a helpful guide to disease activity
[23], though only as one of a series of assessments, of
which the most important relate to clinical symptoms and
signs of disease. In an attempt to improve the value of com-
plement measurements in the assessment of disease activ-
ity, investigators have measured the levels of serum markers
of complement activation, such as anaphylatoxin levels [24],
C1r-C1s-C1 inhibitor complexes [18], C4d levels [25],
iC3b or C3dg levels [26,27] and membrane attack complex
levels [28,29]. Although there is evidence that measure-
ment of these complement activation products correlatesS281
somewhat better with disease activity than measurement of
total C4 and C3 levels [30–32], none of these assays has
been widely adopted in clinical practice. There are two
reasons for this: each of these complement activation prod-
ucts is highly unstable in vivo and therefore difficult to
measure with any useful reliability outside a research
setting; and the plethora of different causes of complement
activation in lupus, which were discussed earlier.
In spite of all of these caveats it is worthwhile to measure
complement activity in patients with SLE. At the onset of
disease, complement measurements may have diagnostic
value. Evidence of complement activation is a marker of
the family of diseases in which immune-complex-mediated
pathology is prominent. Although a rare finding, it is also
important to consider whether a patient might have an
inherited complement deficiency underlying the disease.
Assay of C4 and C3 levels alone may not alert the practi-
tioner to the presence of complement deficiency. Indeed
in the case of C1 deficiency, C4 and C3 levels may be
high because of reduced consumption of classical
pathway proteins [33]. For this reason, a functional assay
of the pathway, such as a CH50, should be considered in
all patients with suspected SLE.
The second diagnostic value of complement measurement
in SLE is that evidence of marked complement activation
should alert the clinician to one of three possibilities. The
first is the presence of anti-C1q antibodies, which I will
discuss below. The second is the presence of haemolytic
anaemia; a Coombs’ test should be performed in patients
in whom this possibility is suspected. The third is the pres-
ence of active disease with the presence of glomeru-
lonephritis. Finally, regular measurements of complement
may disclose changes in complement levels that, when
considered with the clinical findings and the results of
other serological assays, may point towards changes in
disease activity. There is a series of studies (reviewed in
[34]) that show that changes in complement, anti-double-
stranded (ds) DNA and anti-C1q antibody levels may
predict the onset of disease flares [23,35–39].
Complement activation on cells and in tissues
Many tissues from patients with SLE show deposits of
antibodies and complement proteins [7,40]. The demon-
stration of these in biopsies can be of diagnostic value,
for example as part of the characterization of the histology
of renal biopsies, or at the dermo-epidermal junction in
the skin.
There is usually a correlation between the presence of
antibody deposits and the presence of complement pro-
teins. However, there is no simple correlation between the
presence of antibody or complement deposits and the
presence of tissue inflammation. For example, biopsies of
clinically normal skin typically show deposits of antibody
and complement at the basement membrane at the
dermo-epidermal junction, and this has some diagnostic
value for SLE, known as the ‘lupus band’ test. Attempts
have been made to identify markers of complement activa-
tion in tissues that correlate better with the presence of
inflammation. One such marker is the presence of the
membrane attack complex, which is more prominent in
inflamed tissues compared with clinically normal tissues
from patients with SLE [41–44]. Complement may also be
detected on the cellular elements in blood and this is
especially prominent in patients with autoimmune
haemolytic anaemia or thrombocytopenia as part of the
spectrum of disease.
Red cells and CR1
Erythrocytes in primates bear a complement receptor
known as complement receptor type 1, usually abbrevi-
ated as CR1 (reviewed by [45]). Alternative names for this
protein include the immune adherence receptor and
CD35. The receptor has specificity for C3b, C4b and
iC3b, in order of binding strength (C3b highest). On ery-
throcytes CR1 is present at low copy number (between
70 and 700 molecules per cell) but is organized in clus-
ters that allow high avidity binding. Erythrocyte CR1 levels
in patients with SLE are reduced, and before discussing
the explanation and possible significance of this finding, a
brief preamble will be given describing the biology of this
interesting molecule.
Complement receptor type 1 has several biological activi-
ties. It acts as a binding and transport molecule for parti-
cles in the circulation bearing C3b clusters, for example
parasites and bacteria. Red cells are thought to act as
particulate carriers of pathogens bearing C3b and C4b in
the circulation, transporting them to the fixed mononuclear
phagocytic system in the liver, spleen and bone marrow.
Complement also has a biochemical activity as a cofac-
tor to the serine esterase factor I in the cleavage of C3b
to inactive products. Factor I cleaves C3 sequentially to
iC3b, then to C3dg plus C3c. Factor I may use one of
several cofactors for the first cleavage reaction, includ-
ing the plasma protein, factor H, and the cell membrane
proteins CR1 or membrane cofactor protein (also known
as CD46). However, CR1 is the sole known cofactor for
the second cleavage reaction by factor I of iC3b to
C3dg and C3c.
Complement receptor type 1 is also present on other cell
types, including B cells (on which ligation of complement
receptors modulates the threshold for B cell activation),
neutrophils and other phagocytic cells on which CR1 con-
tributes to the recognition, uptake and destruction of parti-
cles such as pathogens or immune complexes carrying C3
and C4 split products. Finally CR1 is present on antigen-
presenting cells and reservoirs of antigen such as follicular
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dendritic cells that act as a long-lived ‘sump’ of foreign
antigens, preserving immunological memory.
It had been known since the 1930s that there was varia-
tion between normal humans in the expression of CR1
levels on erythrocytes [46], and a study in the 1960s pro-
vided evidence that this variation was inherited [47].
These studies were lost in the pre-Medline mists but inter-
est in CR1 in SLE was aroused when it was discovered
that erythrocyte CR1 levels were reduced on the erythro-
cytes of patients with SLE [48] and evidence emerged
that inherited factors might contribute to this reduction
[49,50]. However, there is now a large body of evidence
(reviewed in [51]) that shows that CR1 levels on erythro-
cytes from patients with SLE are reduced as a conse-
quence of disease activity [52]. In addition, although there
is a genetic polymorphism that determines CR1 levels on
normal erythrocytes [53], the distribution of the allele of
CR1 associated with reduced CR1 expression shows no
increase in frequency amongst patients with SLE [54,55].
Most data now point to low levels of CR1 in SLE being
caused by the removal of the receptor from the cell. This is
associated with evidence of complement activation in the
vicinity of red cells with low CR1 numbers (i.e. a correla-
tion has been found between raised levels of C3dg
deposited on erythrocytes and reduced CR1 numbers
[56]). Erythrocytes that were transfused into patients with
SLE rapidly lost CR1 expression from the cell surface
[57]. Similarly, when the formation of immune complexes
in vivo was monitored in humans, clearance of immune
complexes was accompanied by deposition of C4 and C3
on erythrocytes and loss of CR1 from these cells [58].
Proteolysis of the receptor, which is highly susceptible to
cleavage by trypsin-like enzymes [59], is the most likely
mechanism for loss of the receptor from erythrocytes
[60,61]. Studies in nonhuman primates have shown that
when erythrocytes are infused bearing immune complexes
ligated to CR1 there is concerted removal of immune
complexes from erythrocytes together with a reduction in
CR1 levels [62–64]. This reaction, including the loss of
CR1, has been modeled in vitro by studying the transfer of
immune complexes from erythrocytes to macrophages
[65]. Indeed, loss of erythrocyte CR1 may be a physiologi-
cal release mechanism that facilitates the transfer of
opsonised immune complexes and pathogens from red
cells to tissue macrophages.
CR1 levels are also low on certain other cell types in SLE,
most notably on glomerular epithelial cells [66,67].
Soluble CR1 was detected in the urine of patients with
SLE on microvesicles that were derived from kidney
tissue, most probably from glomerular podocytes [68].
Both enhanced microvesiculation and proteolytic cleavage
are candidates for the mechanism of removal of CR1 from
podocytes in SLE [69,70].
Autoantibodies to complement proteins in patients with
SLE
A series of autoantibodies have been described that bind
with high affinity to complement proteins. The majority of
these are directed to ‘neoepitopes’. These are defined as
epitopes that are not expressed in the native protein and
are only exposed in protein that has been modified by a
change in structure. Such a change in structure to reveal a
neoepitope may follow proteolytic cleavage, a conforma-
tional change following activation or following binding of
the protein to another protein. Amongst the earliest
autoantibodies to complement proteins to be identified
were immunoconglutinins and these have been found in
the sera of patients with SLE [71,72]. These autoantibod-
ies bind to an activation product of C3 known as iC3b and
are something of an esoteric curiosity since, although
quite common, they have never been shown to play any
direct role in disease.
In contrast, subsequently identified autoantibodies to com-
plement proteins are more malign. They include C3
nephritic factor, associated with partial lipodystrophy, and
a form of mesangiocapillary glomerulonephritis with elec-
tron dense deposits in glomerular basement membranes.
A small number of patients with C3 nephritic factor and
SLE have been identified [73]. Another important, albeit
rare, autoantibody to a complement protein is anti-C1
inhibitor autoantibody [74,75], occurring particularly in
some patients with lymphoma [76–78].
In SLE, the most important autoantibody to a complement
protein is anti-C1q, which is found in approximately a third
of patients with SLE. In the next few paragraphs I will
review the nature and significance of anti-C1q autoantibod-
ies. Before doing so I should note that other autoantibodies
to complement proteins that have been described in a
small number of patients with SLE are against CR1 [79,80]
and against the C4b2a C3 classical pathway convertase
enzyme [81]. These antibodies are similar to immunocong-
lutinins in being of doubtful pathological significance.
Autoantibodies to C1q in hypocomplementaemic urticarial
vasculitis
The major clinical features of the clinical syndrome
hypocomplementaemic urticarial vasculitis (HUVS) are
well encompassed by its cumbersome name. This syn-
drome is associated with evidence of intense activation of
the classical pathway, with very low levels of C1q, C4 and
C2, and moderately reduced levels of C3, in serum
samples from patients. This syndrome is defined serologi-
cally by the presence of very high titres of autoantibodies
to C1q [82], which were identified originally as C1q pre-
cipitins [83]. These autoantibodies react with a neoepi-
tope in the collagenous region of C1q that is not exposed
in the C1 complex, comprising one molecule of C1q com-
bined with two C1r and two C1s molecules. The epitope
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is only exposed when the C1 complex is activated with the
removal of the C1r and C1s molecules in combination
with C1 inhibitor.
In addition to chronic urticaria, with its accompanying
cutaneous leukocytoclastic vasculitis, other clinical fea-
tures of the disease can include angioedema, glomeru-
lonephritis, neuropathy and airways obstruction [84]. No
other autoantibodies have been identified in HUVS but
some of the features of this syndrome may be found in
patients with ‘full-blown’ SLE who also have anti-C1q
autoantibodies. The relationship between HUVS and SLE
is analogous to that between the primary antiphospholipid
syndrome and SLE. In the case of the latter association,
patients with the primary antiphospholipid syndrome have
a clinical syndrome of recurrent thromboses and abortions
in the presence of autoantibodies to cardiolipin and to β2-
glycoprotein-I. Approximately a third of patients with SLE
also have these autoantibodies as part of their autoanti-
body spectrum and may also have some of the clinical fea-
tures of the antiphospholipid syndrome.
Anti-C1q autoantibodies in SLE
During the 1970s and 1980s there was a great deal of
interest in trying to measure pathogenic immune com-
plexes in those diseases that were thought to be mediated
by immune complexes (reviewed in [85]). Very many
assays were devised, including two based on the capacity
of immune complexes to activate complement by the
binding of C1q. These assays were the fluid phase and
solid phase C1q-binding assays. The fluid phase assay
was conducted by adding radiolabelled C1q to serum;
some of this bound to immune complexes and the bound
material could be measured as a coprecipitate with the
immune complexes by addition of polyethylene glycol
[86,87]. The solid phase C1q-binding assay was con-
ducted by incubating serum samples in microtitre plates
coated with C1q [88]. Immune complexes were thought to
bind to the C1q and could be detected using labelled
antiglobulins that bound to the antibodies within the
immune complexes. Positive results for ‘immune com-
plexes’ using both of these assays were found in patients
with SLE and correlated with the presence of active
disease, the presence of hypocomplementemia and ele-
vated titres of anti-DNA antibodies [86,87,89,90]. There
was a poor correlation, however, between results obtained
using the fluid phase and solid phase C1q-binding assays
[91]. It was subsequently discovered that the explanation
for this discrepancy was that the solid phase C1q-binding
assay is mainly a measure of autoantibodies to C1q rather
than of immune complexes. This was discovered in the fol-
lowing way.
Agnello and colleagues [83] had observed that C1q pre-
cipitins could be characterized in a small number of
patients with SLE and some of these sedimented at 7S,
the sedimentation constant of monomeric IgG. These
observations were confirmed in two further studies of the
size of ‘immune complexes’ in the sera of patients with
SLE [92,93]. These results raised the possibility that the
C1q binding activity was attributable to an autoantibody
rather than to circulating immune complexes that could
bind C1q. This was found to be the case [94–96] and it
was shown that the majority of IgG binding to C1q in solid
phase assays was attributable to autoantibodies reacting
with a neoepitope in the collagenous portion of C1q [97].
The assay has now been adapted to provide a specific
measurement of anti-C1q autoantibodies. The adaptation
to give this specificity is simply the addition of sodium
chloride (1M) during the incubation step of serum with the
C1q-coated plates. This high ionic strength prevents the
binding of immune complexes to C1q but is insufficient to
prevent high affinity binding of antibody to antigen [98].
The ready availability of simple quantitative assays for
autoantibodies to C1q has allowed many studies of the
prevalence and clinical association of C1q autoantibodies
in patients with SLE (reviewed in [99]). The main conclu-
sions of these are as follows. Approximately a third of
patients with SLE have elevated levels of anti-C1q anti-
bodies and these patients often have severe disease
[100]. Several studies have shown an association
between the presence of anti-C1q autoantibodies and
glomerulonephritis [39,101–105]. There is usually evi-
dence of intense activation of the classical pathway of
complement, with very low C1q and C4 levels. A small
number of patients with high titres of anti-C1q autoanti-
bodies have been described with angioedema, resembling
that of hereditary angioedema. These patients have low
levels of C1 inhibitor and of classical pathway comple-
ment proteins [106]. Levels of C3, which tend to be well
maintained in patients with SLE, probably because of
effective regulation of classical pathway activation by C4
binding protein, may be substantially below the normal
range in patients with anti-C1q autoantibodies [107].
Autoantibodies to C1q have been described in mice with
lupus-like disease as well as in humans [108,109].
The association between the presence of anti-C1q
autoantibodies and classical pathway, both in HUVS and
SLE, leads to the obvious question, which is whether the
C1q autoantibodies cause or amplify the classical
pathway activation. There is not a certain answer to this.
Simply adding anti-C1q antibodies to normal serum does
not cause complement activation [110], which may reflect
the fact that these autoantibodies are to a neoepitope of
C1q not expressed in the intact C1q complex. A more
likely explanation is that anti-C1q antibodies fix to C1q
that is bound to immune complexes on cells and within
tissues and that this causes the amplification of the com-
plement activation by immune complexes. There is some
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experimental evidence in support of this hypothesis [111].
An alternative theory is that anti-C1q antibodies arise in
response to intense activation of the classical pathway
with large-scale exposure of an autoantigenic neoepitope
in C1q, and that the anti-C1q antibodies are a conse-
quence and not a cause of the complement activation. As I
will discuss below, the correct answer may be a combina-
tion of these hypotheses.
Complement deficiency is associated with the
development of SLE
Homozygous hereditary deficiency of each of the early
proteins of the classical pathway of complement activation
is very strongly associated with the development of SLE
[112]. Indeed such deficiencies are the strongest disease
susceptibility genes for the development of this disease
that have been characterised in humans. The association
shows a hierarchy of prevalence and disease severity
according to the position of the protein in the activation
pathway. The most prevalent and most severe disease is
associated with deficiency of the proteins of the C1
complex and with total C4 deficiency. More than 75% of
all individuals with deficiency of one of these proteins have
SLE, which is commonly severe. By contrast, C2 defi-
ciency is associated with a much lower prevalence of
disease, estimated at approximately 10%. Deficiency of
C3 is only very uncommonly associated with the develop-
ment of SLE, but because of the rarity of homozygous C3
deficiency, only limited data exist [113].
These clinical data suggest that there is an activity of the
early part of the classical pathway of complement that is
protective in normal individuals against the development of
SLE. Deficiency of this activity predisposes very strongly
to the development of disease, as shown by the observa-
tion that almost every human, so far identified, who lacks
C1q has developed SLE.
It is always a concern that a reported disease association
is due to an ascertainment artefact rather than due to a
true causal association. In the case of complement and
SLE, it could be argued that because complement is fre-
quently measured in patients with SLE, it is not surprising
that complement deficiency turns up in these patients.
There is a group of arguments that militate against this
artefactual explanation for the association. Complement
deficiency has been sought in large normal populations,
but no classical pathway deficiencies have been identified.
The clearest example is the enormous study of Japanese
blood donors, amongst whom no hereditary classical
pathway deficiency states were found [114,115]. There is
a reported Japanese patient, however, with C1q defi-
ciency and SLE [116]. Another argument is that the
observed intrafamilial disease concordance for SLE in
combination with complement deficiency is extremely high.
In the case of C1q deficiency it is more than 90%, a figure
that far exceeds the observed concordance of SLE
between siblings in monozygotic twin pairs (24%) [117].
The third argument is that disease associated with heredi-
tary complement deficiency tends to be of early onset and
the male to female ratio approximates to unity, unlike the
high female preponderance amongst the majority of SLE
patients without complement deficiency.
Each of these observations illustrates the strength of the
disease association and provides evidence that the associ-
ation between complement deficiency and SLE is not likely
to be explained by ascertainment artefact. A further argu-
ment for a causal link is the finding that acquired comple-
ment deficiency states also predispose to the development
of SLE. There is an increased prevalence of SLE amongst
patients with hereditary angioedema who, because of
inherited partial deficiency of C1 inhibitor, fail to regulate
classical pathway complement activation [118–120] and
amongst patients with C3 nephritic factor [73].
This evidence leaves no doubt that homozygous classical
pathway protein deficiencies are causally associated with
the development of SLE. There is less certainty in the case
of partial inherited complement deficiencies. There has
been particular interest in the associations between partial
deficiencies of C4 and SLE. In humans, C4 is encoded by
two tandemly duplicated genes within the major histocom-
patibility complex (MHC), encoding respectively isotypes
known as C4A and C4B [121]. In common with other
MHC genes, each of the C4 genes is highly polymorphic
and, included in the polymorphisms, are null alleles from
which no protein is produced. These null alleles are very
common and approximately 6% of most populations have
homozygous deficiency of either C4A or C4B. It should be
noted that total C4 deficiency is exceptionally rare
because haplotypes encoding null alleles at both the C4A
and C4B loci are very rare. The functions of the two C4
isotypes differ slightly. The internal thioester bond of C4A
shows preferential binding to amino groups with the for-
mation of covalent amide bonds between C4A and pro-
teins. Preferential binding to hydroxyl groups is shown by
C4B, typically in carbohydrates, forming ester linkages
[122].
There are disease susceptibility genes for SLE in the MHC
(reviewed in [123,124]). Following the discovery of the
two isotypes of C4 and the existence of null alleles at both
loci there have been many studies to attempt to determine
whether null alleles of C4 might play a role in determining
disease susceptibility. Initial studies showed an increased
prevalence of C4A null alleles in Caucasoid patients with
SLE [125,126]. However, null alleles for C4A are found
commonly in a particular MHC haplotype, HLA-A1, B8,
C4AQ0, C4B1, DR3, and it is exceptionally difficult to
determine which is the real susceptibility gene or genes
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for SLE and which are the ‘passengers’. The literature
abounds with case-control and family studies either con-
firming or refuting associations between C4 null alleles
and SLE. A definitive answer is likely to emerge in the next
few years as large scale genotyping methods are applied
to the very large family collections of patients with SLE
that are being formed around the world.
What is the explanation for these clinical
findings?
The role of complement in the pathogenesis of
inflammatory lesions in SLE
The traditional view of the pathogenesis of SLE is that
immune complexes containing autoantigens and autoanti-
bodies activate complement, and that this causes inflam-
matory injury to tissues. Although this model is biologically
plausible, it cannot account for all of the clinical observa-
tions that link the complement system and SLE. In particu-
lar, the observation that complement deficiency causes
lupus is hard to reconcile with the concept that comple-
ment activation products are the major cause of inflamma-
tory injury in the disease.
The development of gene-targeted strains of mice that
lack individual protein constituents of inflammatory path-
ways has led to a plethora of apparently inconsistent find-
ings on mechanisms of immune-complex-mediated
inflammation. There is a large array of mice lacking com-
plement proteins and Fc receptors, and an equally large
array of studies of these mice. In this section the mecha-
nisms of complement activation in SLE will be reviewed
briefly and the pathogenesis of inflammation caused by
immune complexes will be considered.
How is complement activated in SLE?
The cause of complement activation in SLE is the forma-
tion of immune complexes, which in turn activate comple-
ment, predominantly by means of the classical pathway.
Complement activation is normally measured in clinical
practice by estimation of antigenic levels of both C3 and
C4, and measured functionally using the CH50 assay. In
the majority of patients with moderate or active SLE,
reduced levels of C4 are detected, with the level of C3
varying between normal to slightly reduced. The CH50 is
typically below normal.
Up to 25% of patients with SLE, however, may have much
more dramatic reductions in C4 levels, typically associ-
ated with significantly subnormal C3 levels and CH50.
Three subsets of patients make up the majority of these
individuals. There are those subjects who have evidence
of autoimmunity to red blood cells. This may manifest as
overt autoimmune haemolytic anaemia, but it may be more
subtle and be detectable only by means of direct antiglob-
ulin test (Coombs’ test) positivity for IgG, C3 and C4
deposition on red cells. Some of these patients also have
antiphospholipid (also known as anticardiolipin) autoanti-
bodies. A study in a murine model of the antiphospholipid
syndrome has recently shown that antiphospholipid anti-
bodies cause foetal resorption by means of complement
activation in the decidua in the pregnant uterus [127]. The
complement activation at this site was shown to cause
inflammatory injury, which appeared to be responsible for
the foetal death and resorption.
Another subset comprises patients with very systemic
disease, typically associated with high levels of anti-
dsDNA autoantibodies and, sometimes, with the presence
of type III cryoglobulins [128] in serum containing poly-
clonal IgG and C3.
The third group of patients comprises those individuals
who have anti-C1q autoantibodies. These subjects often
have the most severe evidence of classical pathway com-
plement activation, with profoundly reduced C4 levels and
moderate to substantial reductions in C3 levels. It is
thought that anti-C1q autoantibodies are the cause and not
the consequence of the complement activation measured
in serum, and possible mechanisms were reviewed above.
Mechanisms of immune-complex-mediated injury
Until very recently it was believed that tissue injury in SLE
was caused by the formation of immune complexes that
caused complement activation, which in turn caused
inflammatory injury. Tissue injury was thought to be medi-
ated by the direct effects of activation of the triggered
enzyme cascades of complement, coagulation and kinin
pathways, coupled with an influx of inflammatory cells,
including polymorphonuclear leukocytes and monocytes.
The activities of complement in the mediation of inflamma-
tion include the ligation of complement receptors for the
opsonic components of complement subcomponents C3b
and C4b, the effects of the anaphylatoxins C5a and C3a,
and the effects of insertion of sublethal amounts of the
membrane attack complex into cell membranes.
The development of mice with null mutations in selected
proteins of inflammatory pathways has enabled the
precise dissection of their role in both host defence and
the causation of inflammatory injury. There are many exper-
imental models of injury caused by immune complexes and
the use of these in gene-targeted mice has led to a reap-
praisal of the role of complement and Fc receptors in
inflammatory responses to immune complexes. The major
conclusions from these experiments are as follows. Firstly,
it is clear that all immune complexes are not equal in the
manner in which they cause tissue injury. The site of
immune complex formation [129], the species [130] and
strain [131] of animal, and the nature of the antigen [132],
as well as the antibody, may affect the inflammatory
response. Secondly, in many models it has been found
that the ligation of Fc receptors by immune complexes is
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the dominant cause of tissue injury, and complement plays
no important role in the induction of tissue injury [133].
Indeed, in experimental models of complement deficiency,
it has been shown that immune-complex-mediated
glomerulonephritis can develop spontaneously in the pres-
ence of genetic deficiency of the complement activation
pathways [134,135]. In other experimental models,
however, complement activation, and in particular C5a
production, have been found to be essential for the full
expression of tissue injury [136]; inhibition of C5a activity
is therapeutic [137]. Thirdly, it has been found that com-
plement may provide some degree of protection against
inflammatory injury induced by immune complexes in some
models of experimental glomerulonephritis [138]. We will
consider possible mechanisms for this in a subsequent
section of this chapter. Finally, it is clear that in mice and
humans, inflammatory pathways that operate downstream
from the activation of complement, and the ligation of Fc
and complement receptors play crucial roles in the expres-
sion of inflammation that is mediated by immune com-
plexes [139].
Complement deficiency and SLE
The associations of complement deficiency with SLE have
been reviewed in the Introduction. Here we shall consider
three hypotheses that have been advanced to explain the
mechanism of the association. The first two of these are
closely related, proposing mechanisms that could operate
in tandem. These hypotheses are that complement pre-
vents the development of SLE through a role in the pro-
cessing and clearance from the body of immune
complexes, and dying and dead cells. In the absence of
these activities, autoantigens may be presented to the
immune system in the context of inflammatory injury and
this may drive the development of autoimmunity. The third
hypothesis invokes a role for complement in the develop-
ment of self-tolerance to the autoantigens of SLE, and pro-
poses that B cells with specificity for lupus autoantigens
are not effectively silenced or eliminated in the absence of
complement. Each of these hypotheses will be explored
briefly in this section.
Complement and immune complex processing
Michael Heidelberger in the 1940s demonstrated a role
for complement in the modification of immune complex
lattices [140]. Since then there have been many studies
that showed that complement promotes the inactivation
and clearance of immune complexes by two main mech-
anisms. One of these is the reduction in the size of
immune complex lattices (reviewed in [141,142]). This
is achieved by the interaction of C1q with immune com-
plexes, which interferes with Fc–Fc interactions that
stabilize immune complexes, and by the covalent
binding of C4b and C3b to antigens within the immune
complexes. This binding interferes with the binding of
antigen to antibody by effectively reducing the valency
of antigen for antibody. As well as reducing the size of
immune complexes, complement provides additional
ligands within the immune complex, promoting the clear-
ance of immune complexes by complement as well as
Fc receptors. As discussed in earlier in this chapter,
immune complexes that have bound C4b and C3b can
bind to CR1 on erythrocytes in the circulation that
promote the clearance of immune complexes to the
fixed mononuclear phagocytic system.
These observations led to the hypothesis that complement
deficiency may promote the development of SLE by
impairment of the normal mechanisms for clearance and
processing of immune complexes. These could cause
inflammatory injury in tissues, resulting in the release of
autoantigens in an inflammatory context, promoting the
development of an autoimmune response [143]. There is
abundant evidence that immune complex processing in
SLE is abnormal and related to abnormal complement
function [144–146]. Both the discovery that complement
deficiency is compatible with the normal spontaneous
development of glomerulonephritis in murine models of
SLE [134,135] and the surprising finding that induced
glomerulonephritis may be exacerbated in the presence of
complement deficiency [147] are compatible with this pro-
posed role for complement in protection against immune-
complex-mediated injury.
This hypothesis is complementary to and was the precur-
sor of the ‘waste disposal’ hypothesis, developed in the
next section, which advances the hypothesis that comple-
ment provides protection against the development of SLE
by impairment of the physiological waste disposal of
autoantigens released by dying and dead cells.
Complement and the clearance of apoptotic cells
A central question about the aetiology of SLE is to under-
stand how an autoimmune response develops to autoanti-
gens that are found ubiquitously in cells of the body. There
is abundant evidence that the established autoantibody
response in SLE is driven by the actual autoantigens (as
opposed to being part of a polyclonal antibody response
or driven by cross-reacting antigens). What is the source
of these autoantigens? Cell death is an obvious potential
source of autoantigens that are otherwise hidden from
immune receptors in the heart of living cells. However, cell
death is a highly regulated process and the normal mecha-
nisms of apoptosis ensure that dying cells are cleared
without the induction of tissue inflammatory responses
[148]. One possible source is dead or dying cells from
sites of inflammation and tissue injury. A possible connec-
tion between apoptotic cells and the autoantibody
response of SLE was established by Rosen and his col-
leagues, who showed that a number of lupus autoantigens
were located at the surface of apoptotic bodies and on
apoptotic blebs [149].
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These observations have been followed by a series of
studies of the mechanisms of apoptotic cell clearance in
SLE. It was shown that macrophages derived from
peripheral blood of patients with SLE showed defective
uptake of apoptotic cells [150]. The idea that comple-
ment might play a role in the clearance of apoptotic
cells came from the observation that C1q bound to
apoptotic keratinocytes [151]. An excess of apoptotic
cells was observed in kidneys from C1q-deficient mice
[152]. It was later shown that elicited peritoneal
macrophages from C1q-deficient mice showed defec-
tive clearance of injected apoptotic thymocytes and the
human lymphocyte cell lines known as Jurkat cells
[153]. Similarly, monocyte-derived macrophages from a
small number of C1q-deficient humans showed defec-
tive clearance of apoptotic cells, a defect that could be
reversed by the addition of purified C1q. It was also
found that the clearance of apoptotic cells could be
mediated by bound C3 [154], although there may be an
additional role for earlier proteins of the classical
pathway in mediating and/or augmenting apoptotic cell
clearance. This work has led to the hypothesis that com-
plement plays a role in the prevention of autoimmunity
through a role in the disposal of dying and dead cells.
Absence of this activity, possibly occurring in the
context of an inflammatory environment, may promote
the development of an autoantigen-driven autoimmune
response [155,156]. It has also been shown that C4-
deficient mice are prone to the development of lupus-
like autoimmunity [157,158], which provides further
evidence that complement-deficient mice are a useful
model to study the association between complement
deficiency and SLE, first described in humans.
The steps from defective clearance of apoptotic cells to
the development of an autoimmune response remain
unknown. At least in mice, there is evidence that other
genes contribute to the autoimmune phenotype in the
context of C1q deficiency, which is associated with lupus
in mice on a hybrid (129 strain × C57/BL6 strain) back-
ground. It also causes disease acceleration in the lupus
prone MRL.mp mouse. However, no autoimmunity is seen
in C1q-deficient mice on 129 and C57/BL6 inbred
strains [152,159]. These data show the necessity for the
presence of other disease-modifying genes that enable
the potential autoimmune consequences of C1q defi-
ciency to be expressed in mice. In humans, the strength
of the contribution of C1q deficiency to disease appears
higher than in mice, as the majority of humans with C1q
deficiency express some manifestations of SLE [112].
However, only approximately a third of patients develop
glomerulonephritis, again indicating that C1q deficiency
is not sufficient for the development of glomerular inflam-
mation. Lupus in humans and mice is subject to the
influence of multiple genetic and, probably also environ-
mental, factors.
Complement and the induction of tolerance
An alternative hypothesis to explain the link between com-
plement deficiency and SLE is that complement plays a
role in the induction of tolerance to autoantigens [160].
Deficiency of this activity disturbs the normal tolerance
mechanisms of lymphocytes leading to the induction of
SLE. This hypothesis is difficult to reconcile with the
observations that the complement system plays a physio-
logical role in the augmentation of antibody responses.
Pepys showed many years ago that depletion of comple-
ment C3 was associated with reduced primary and sec-
ondary antibody responses to T-cell-dependent antigens
[161], a finding that has subsequently been reproduced in
complement genetically-deficient mice and guinea pigs
[162,163]. The corollary of these observations was the
engineering of complement as an adjuvant by the covalent
attachment of oligomers of C3d to an experimental
antigen [164].
Using a transgenic model to study tolerance to hen egg
lysozyme, expressed as an autoantigen, it was found that
tolerance was disturbed in C4-deficient, but not C3-defi-
cient, mice [165]. In similar experiments with C1q-defi-
cient mice, however, tolerance induction to hen egg
lysozyme as an autoantigen was normal [166]. This model
of tolerance induction has important limitations as a model
for exploring SLE, as in this disease, the majority of the
autoantigens are cell-associated, as will be reviewed in
the next section. Experimental studies are underway
exploring the role of complement deficiency in tolerance
induction in experimental animals expressing transgenic
lupus autoantibodies, which may provide a clearer test of
the hypothesis that complement is involved in the induc-
tion of tolerance.
A unifying hypothesis that links C1q deficiency, C1q
autoantibodies and SLE
A prominent feature of the autoantibody response in SLE
is that it is directed not against isolated proteins but typi-
cally against whole complexes of proteins and nucleic
acids [167–169]. Autoantibodies are found in clusters
reactive against the different protein, nucleic acid and
phospholipid components of these complexes. For
example anti-dsDNA autoantibodies are usually associ-
ated with antihistone autoantibodies and antibodies react-
ing with conformational determinants of chromatin. The
autoantigens in this case are thought to be nucleosomes.
Anti-Sm and antiribonucleoprotein specificities are
directed against different proteins in the spliceosome
complex. Anti-Ro and anti-La are directed against the
major protein component of a small cytoplasmic ribonucleo-
protein complex. These clinical findings point to actual
autoantigenic particles in lupus being these large com-
plexes and there is evidence that B cells play a key role as
antigen-presenting cells in lupus [170–172]. A B cell
bearing an antigen receptor for a component of one of
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these complexes can internalize the complex and then act
as antigen-presenting cell for other peptides within the
complex. In this way it is likely that the autoantibody
response in SLE is diversified and amplified.
How do these data explain how on the one hand C1q defi-
ciency causes SLE and on the other that SLE causes an
autoantibody response to C1q? The hypothesis has been
reviewed above that C1q and other complement proteins
prevent lupus by binding to apoptotic and necrotic cells
and promoting their clearance. The absence of C1q pro-
motes autoimmunity by allowing these autoantigens to
drive an autoimmune response.
This hypothesis implies that C1q binds to the autoanti-
gens of SLE. In doing so, it may itself become part of the
autoantigenic complexes that characterize the disease.
Although it is unusual for plasma proteins to be targets for
the autoimmune response in SLE, there is an important
and informative analogy. Approximately a third of patients
with SLE develop antiphospholipid autoantibodies. These
are directed against negatively charged phospholipids,
especially phosphatidylserine, which normally reside on
the inner lamella of cell membranes. However, they are
translocated to the outer lamella of apoptotic cells, which
reinforces the possible role of these cells as the source of
the autoantigens that drive SLE [173,174]. Antiphospho-
lipid autoantibodies in SLE are typically associated with an
autoantibody response to the plasma proteins β2-glyco-
protein-I and annexin V, that binds to negatively-charged
phospholipids [175,176].
Thus, the observation that C1q is itself an autoantigen in
many patients with SLE reinforces the hypothesis that
C1q and the complement system may prevent disease by
binding to and promoting the clearance of autoantigens.
Complement and the treatment of disease
It is not straightforward to treat SLE by the manipulation of
the complement system. On the one hand complement
deficiency, as we have seen, is a powerful cause of SLE
and this provides arguments for increasing complement
activity by repletion of classical pathway proteins, at least
in the case of the rare hereditary deficiencies. On the
other hand, there is evidence that complement, especially
the anaphylatoxins and the membrane attack complex,
may be a cause of tissue injury and this raises the possibil-
ity of the treatment of SLE by therapeutic inhibition of the
complement system. Both approaches to therapy have
been attempted in different contexts in SLE and will be
reviewed in the next few paragraphs.
Complement is a potent cause of tissue injury in
ischaemia-reperfusion injury and therefore is a therapeutic
target in patients with myocardial infarction and stroke.
Because these are highly prevalent and disabling diseases
there have been many studies that have validated the
potential importance of complement inhibition as a treat-
ment for them. There are several reviews that illustrate the
range of diseases that are under investigation and the
many approaches to treatment by inhibition of the comple-
ment system [177–182].
Anti-C5 therapy
There is increasing evidence that the key mediators of
injury induced by the complement system are the anaphy-
latoxins, especially C5a, and the membrane attack
complex. An anti-C5 monoclonal antibody reduced the
expression of glomerulonephritis and increased the lifes-
pan of NZB/W F1 hybrid mice [183]. Similar anti-C5 anti-
bodies have also been found to be therapeutically
effective in other disease models where complement is
thought to play an important role, such as ischaemia-
reperfusion injury in the heart [184] and hyperacute
xenograft rejection [185]. There have been preliminary
studies of this approach to treatment in humans undergo-
ing coronary artery bypass surgery on cardiopulmonary
bypass, which is known to be a potent means of activating
the complement system [186].
These studies, however, have to be balanced against the
findings that lupus nephritis may develop in humans
lacking classical pathway proteins and in mice which are
either unable to activate C3 [134] or genetically deficient
in this protein [135]. Trials have been proposed of anti-C5
therapy in patients with SLE and nephritis.
Complement repletion therapy
Given that deficiency of classical pathway complement
proteins is a potent cause for the development of SLE,
one obvious approach to therapy is replacement of the
missing protein. However, there are potential pitfalls to this
approach. Purified or engineered complement proteins are
not available for treatment purposes. Therefore, whole
plasma preparations have to be used, which entail all of
the complications of plasma treatment, including hyper-
sensitivity reactions and the potential for transmitted viral
infections. Another pitfall is the possibility that replace-
ment of a missing complement protein in a patient with
months or years of accumulated immune complexes in
tissues may be followed by complement activation in
tissues causing inflammatory injury. A further issue is that,
following exposure to a protein that is genetically deficient
and therefore ‘foreign’, antibodies may develop, preventing
treatment by replenishment.
There are several anecdotal reports of the treatment of
complement-deficient patients with plasma; benefit has
been reported in two patients with C2 deficiency
[187,188]. There was no significant clinical response in a
patient with C1q deficiency who had received briefly fresh-
frozen plasma, but antibodies developed to C1q [189].
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Treatment with plasma of two dogs with hereditary C3 defi-
ciency and mesangiocapillary glomerulonephritis was not
successful and led to a worsening of disease [190].
Many tissues synthesize complement proteins. The bone
marrow is the major source of C1q [191] and this raises
the possibility that C1q replenishment in patients with
C1q deficiency and severe SLE might be achieved by
bone marrow transplantation.
C1q absorption
Another approach that is undergoing experimental evalua-
tion in small numbers of patients with SLE is immunoab-
sorption by perfusion of plasma over columns coupled
with C1q [192,193]. These columns can remove anti-C1q
autoantibodies from serum and may also be capable of
extracting immune complexes from the circulation. This is
an interesting approach, particularly in the light of the evi-
dence discussed above that anti-C1q antibodies may play
a pathogenic role in disease. It is too early to know
whether this approach will have any important role to play
in the management of SLE.
Glossary of terms
C = complement component; CH50 = complement haemo-
lysis  50% test; CR = complement receptor; HUVS =
hypocomplementaemic urticarial vasculitis.
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